Find the right fit for you - faster
Get tailored insights about working at Athersys in one quick step.
Athersys Snapshot
Committed to Developing Therapies to Extend and Enhance the Quality of Human Life.
Athersys is a clinical-stage regenerative medicine company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our current clinical development programs are focused on treating critical care indications where the current standard of care is limited or inadequate for many patients.
MultiStem® (invimestrocel), a patented and proprietary allogeneic stem cell product candidate, is the Company's lead platform product and is currently in clinical development. The Company's most advanced program is focused on the treatment of ischemic stroke, which is currently being evaluated in a registrational trial in Japan and in an ongoing Phase 3 clinical trial in North America under a Special Protocol Assessment and in Europe under a Final Scientific Advice positive opinion. MultiStem is also being evaluated in a pivotal Phase 2/3 study for the treatment of acute respiratory distress syndrome (ARDS), with Fast Track and RMAT designation from the FDA and in a Phase 2 trial evaluating MultiStem for the treatment of traumatic injuries. Stroke, ARDS and trauma represent areas of clinical need for patients, as well as substantial commercial opportunities.
MultiStem® (invimestrocel), a patented and proprietary allogeneic stem cell product candidate, is the Company's lead platform product and is currently in clinical development. The Company's most advanced program is focused on the treatment of ischemic stroke, which is currently being evaluated in a registrational trial in Japan and in an ongoing Phase 3 clinical trial in North America under a Special Protocol Assessment and in Europe under a Final Scientific Advice positive opinion. MultiStem is also being evaluated in a pivotal Phase 2/3 study for the treatment of acute respiratory distress syndrome (ARDS), with Fast Track and RMAT designation from the FDA and in a Phase 2 trial evaluating MultiStem for the treatment of traumatic injuries. Stroke, ARDS and trauma represent areas of clinical need for patients, as well as substantial commercial opportunities.
